Imagine the Phase I trials for stubbed toes -- clinicians in white coats trying to give mice stubbed little toesies. Meanwhile the FDA recommends that we give one dose of Leronlimab, but not till Day 47. Turns out the mice can recover on their own from their stubbed toesies before then, and Leron misses its primary endpoint. The FDA then issues a public letter saying that Leronlimab does not cure stubbed toes in mice or anything else ever and then clamps on a safety hold because the uncle of one of the mice died in its sleep a week before the trial. Dr Jay tries reasoning with the FDA, but they are adamant...

Too close to home?